IL246613B - Dosing regimen of iron trimaltol - Google Patents

Dosing regimen of iron trimaltol

Info

Publication number
IL246613B
IL246613B IL246613A IL24661316A IL246613B IL 246613 B IL246613 B IL 246613B IL 246613 A IL246613 A IL 246613A IL 24661316 A IL24661316 A IL 24661316A IL 246613 B IL246613 B IL 246613B
Authority
IL
Israel
Prior art keywords
dosage regimen
ferric trimaltol
trimaltol
ferric
regimen
Prior art date
Application number
IL246613A
Other languages
English (en)
Hebrew (he)
Other versions
IL246613A0 (en
Original Assignee
Iron Therapeutics Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201400171A external-priority patent/GB201400171D0/en
Priority claimed from GB201418708A external-priority patent/GB201418708D0/en
Application filed by Iron Therapeutics Holdings Ag filed Critical Iron Therapeutics Holdings Ag
Publication of IL246613A0 publication Critical patent/IL246613A0/en
Publication of IL246613B publication Critical patent/IL246613B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL246613A 2014-01-06 2016-07-05 Dosing regimen of iron trimaltol IL246613B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201400171A GB201400171D0 (en) 2014-01-06 2014-01-06 Dosage regimen
GB201418708A GB201418708D0 (en) 2014-10-21 2014-10-21 Dosage regimen
PCT/IB2015/050098 WO2015101971A1 (en) 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol

Publications (2)

Publication Number Publication Date
IL246613A0 IL246613A0 (en) 2016-08-31
IL246613B true IL246613B (en) 2020-05-31

Family

ID=52432872

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246613A IL246613B (en) 2014-01-06 2016-07-05 Dosing regimen of iron trimaltol

Country Status (12)

Country Link
US (1) US10179120B2 (enExample)
EP (1) EP3091974B1 (enExample)
JP (2) JP6556753B2 (enExample)
KR (1) KR102351422B1 (enExample)
CN (2) CN106413706A (enExample)
AU (1) AU2015204192B2 (enExample)
BR (1) BR112016015766A2 (enExample)
CA (1) CA2934836C (enExample)
ES (1) ES2785391T3 (enExample)
IL (1) IL246613B (enExample)
SI (1) SI3091974T1 (enExample)
WO (1) WO2015101971A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2785391T3 (es) 2014-01-06 2020-10-06 Shield Tx Uk Ltd Régimen de dosificación de trimaltol férrico
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
CN109071481B (zh) 2016-03-31 2022-09-30 英国神盾Tx股份有限公司 用于由元素铁产生麦芽酚铁组合物的方法
CN109310667B (zh) * 2016-03-31 2022-01-11 英国神盾Tx股份有限公司 用于治疗或预防癌症和肿瘤的麦芽酚铁组合物
AU2017242901B2 (en) * 2016-03-31 2020-11-19 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
CN109311837B (zh) 2016-03-31 2022-09-30 英国神盾Tx股份有限公司 用于由氢氧化亚铁产生麦芽酚铁组合物的方法
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150213B (it) * 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
RO113611B1 (ro) * 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
DE69633178T2 (de) 1995-06-10 2005-08-11 Vitra Pharmaceuticals Ltd., Saffron Walden Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ES2236300T3 (es) 2000-09-19 2005-07-16 Vitra Pharmaceuticals Ltd. Composiciones de hierro.
US20050118291A1 (en) * 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
US20070087036A1 (en) * 2005-05-03 2007-04-19 Durschlag Maurice E Edible film for transmucosal delivery of nutritional supplements
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
GB201101370D0 (en) * 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
JP5856725B2 (ja) * 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
ES2785391T3 (es) 2014-01-06 2020-10-06 Shield Tx Uk Ltd Régimen de dosificación de trimaltol férrico
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen

Also Published As

Publication number Publication date
JP6556753B2 (ja) 2019-08-07
EP3091974A1 (en) 2016-11-16
IL246613A0 (en) 2016-08-31
KR20160105499A (ko) 2016-09-06
EP3091974B1 (en) 2020-04-01
CN114010629A (zh) 2022-02-08
SI3091974T1 (sl) 2020-08-31
CN106413706A (zh) 2017-02-15
CA2934836C (en) 2022-03-22
AU2015204192B2 (en) 2020-03-26
JP2017501235A (ja) 2017-01-12
JP2019131592A (ja) 2019-08-08
ES2785391T3 (es) 2020-10-06
KR102351422B1 (ko) 2022-01-13
US20160324822A1 (en) 2016-11-10
BR112016015766A2 (pt) 2017-08-08
WO2015101971A1 (en) 2015-07-09
US10179120B2 (en) 2019-01-15
CA2934836A1 (en) 2015-07-09
AU2015204192A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
IL249946A0 (en) High Dose Strength Rocaprib Tablets
PT3110483T (pt) Inalador
IL246613B (en) Dosing regimen of iron trimaltol
PL3363428T3 (pl) Perfuzyjna postać dawkowania
IL247084A0 (en) dose fgh–18
HUE069474T2 (hu) Inhalátor
GB201418710D0 (en) Dosage regimen
AU358579S (en) Inhaler
IL249374A0 (en) Pharmaceutical administration forms
GB201516836D0 (en) Dosing regimen of combination
IL266255A (en) New dosage regimen
HK40065667A (zh) 三麦芽酚铁的剂量方案
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201411345D0 (en) Nicotine dosage regimen
PH32014001154S1 (en) Inhaler
PH32014000866S1 (en) Inhaler
PH32014000796S1 (en) Inhaler
PH32014000795S1 (en) Inhaler
PH32014000794S1 (en) Inhaler
PH32014000332S1 (en) Inhaler

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed